openPR Logo
Press release

Methicillin Resistant Staphylococcus Aureus Pipeline 2024 | Trellis Bioscience, LegoChem Biosciences, Aptorum Group, ContraFect, Crystalgenomics, Cellics Therapeutics, MicuRx, Oxford Antibiotic Group, Destiny Pharma, TSRL, Inc., TAXIS Pharmaceuticals, Bas

06-19-2024 05:57 AM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Methicillin Resistant Staphylococcus Aureus Pipeline

Methicillin Resistant Staphylococcus Aureus Pipeline

DelveInsight's, "Methicillin-Resistant Staphylococcus Aureus Infections Pipeline Insight 2024" report provides comprehensive insights about 25+ companies and 27+ pipeline drugs in Methicillin-Resistant Staphylococcus Aureus Infections pipeline landscape. It covers the Methicillin Resistant Staphylococcus Aureus pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Methicillin Resistant Staphylococcus Aureus pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Methicillin Resistant Staphylococcus Aureus Pipeline Report
• DelveInsight's Methicillin Resistant Staphylococcus Aureus pipeline report depicts a robust space with 25+ active players working to develop 27+ pipeline therapies for Methicillin Resistant Staphylococcus Aureus treatment.
• The leading companies working in the Methicillin Resistant Staphylococcus Aureus Market include Trellis Bioscience, LegoChem Biosciences, Aptorum Group, ContraFect, Crystalgenomics, Cellics Therapeutics, MicuRx, Oxford Antibiotic Group, Destiny Pharma, TSRL, Inc., TAXIS Pharmaceuticals, Basilea Pharmaceutica, Helperby Therapeutics, Akagera Medicines, Histogen, Alphamab Co. Ltd, Biocidium Pharmaceuticals, and others.
• Promising Methicillin Resistant Staphylococcus Aureus Pipeline Therapies in the various stages of development include Linezolid (Zyvox), Vancomycin, Ceftaroline fosamil, Linezolid, Telavancin, Tigecycline, and others.
• January 2024:- AbbVie- A Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Pediatric Subjects With Acute Bacterial Skin and Skin Structure Infections. To determine the safety and descriptive efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections in children, aged birth to 17 years (inclusive), known or suspected to be caused by susceptible Gram-positive organisms, including methicillin-resistant strains of Staphylococcus aureus.

Request a sample and discover the recent advances in Methicillin Resistant Staphylococcus Aureus Treatment Drugs @ Methicillin Resistant Staphylococcus Aureus Pipeline Report- https://www.delveinsight.com/report-store/methicillin-resistant-staphylococcus-aureus-mrsa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

In the Methicillin Resistant Staphylococcus Aureus pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Methicillin-Resistant Staphylococcus Aureus Infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Methicillin Resistant Staphylococcus Aureus Overview
Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most successful modern pathogens. The same organism that lives as a commensal and is transmitted in both health-care and community settings is also a leading cause of bacteraemia, endocarditis, skin and soft tissue infections, bone and joint infections and hospital-acquired infections.

Find out more about Methicillin Resistant Staphylococcus Aureus Therapeutics Assessment @ Methicillin Resistant Staphylococcus Aureus Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/methicillin-resistant-staphylococcus-aureus-mrsa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Methicillin Resistant Staphylococcus Aureus Emerging Drugs Profile
• HY-004B8b: Helperby Therapeutics
• TRL1068: Trellis Bioscience
• Delpazolid (LCB01-0371): LegoChem Biosciences

Methicillin Resistant Staphylococcus Aureus Pipeline Therapeutics Assessment
There are approx. 25+ key companies which are developing the Methicillin-Resistant Staphylococcus Aureus Infections therapies. The Methicillin-Resistant Staphylococcus Aureus Infections companies which have their Methicillin-Resistant Staphylococcus Aureus Infections drug candidates in the most advanced stage, i.e. phase II include, Helperby Therapeutics.

DelveInsight's Methicillin-Resistant Staphylococcus Aureus Infections Pipeline Report covers around 27+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Methicillin-Resistant Staphylococcus Aureus Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.
• Molecule Type

Methicillin-Resistant Staphylococcus Aureus Infections Pipeline Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Learn more about the emerging Methicillin Resistant Staphylococcus Aureus Pipeline Therapies @ Methicillin Resistant Staphylococcus Aureus Clinical Trials Assessment- https://www.delveinsight.com/sample-request/methicillin-resistant-staphylococcus-aureus-mrsa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Methicillin Resistant Staphylococcus Aureus Pipeline Report
• Coverage- Global
• Methicillin Resistant Staphylococcus Aureus Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Methicillin Resistant Staphylococcus Aureus Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Methicillin Resistant Staphylococcus Aureus Companies- Trellis Bioscience, LegoChem Biosciences, Aptorum Group, ContraFect, Crystalgenomics, Cellics Therapeutics, MicuRx, Oxford Antibiotic Group, Destiny Pharma, TSRL, Inc., TAXIS Pharmaceuticals, Basilea Pharmaceutica, Helperby Therapeutics, Akagera Medicines, Histogen, Alphamab Co. Ltd, Biocidium Pharmaceuticals, and others.
• Methicillin Resistant Staphylococcus Aureus Pipeline Therapies- Linezolid (Zyvox), Vancomycin, Ceftaroline fosamil, Linezolid, Telavancin, Tigecycline, and others.

Dive deep into rich insights for new drugs for Methicillin Resistant Staphylococcus Aureus Treatment, Visit @ Methicillin Resistant Staphylococcus Aureus Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/methicillin-resistant-staphylococcus-aureus-mrsa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Methicillin-Resistant Staphylococcus Aureus Infections: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Methicillin-Resistant Staphylococcus Aureus Infections - DelveInsight's Analytical Perspective
7. Mid Stage Products (Phase II)
8. HY-004: Helperby therapeutics
9. Drug profiles in the detailed report…..
10. Early Stage Products (Phase I)
11. TRL1068: Trellis Bioscience
12. Drug profiles in the detailed report…..
13. Preclinical and Discovery Stage Products
14. EVX B1: Evaxion Biotech
15. Drug profiles in the detailed report…..
16. Inactive Products
17. Methicillin-Resistant Staphylococcus Aureus Infections Key Companies
18. Methicillin-Resistant Staphylococcus Aureus Infections Key Products
19. Methicillin-Resistant Staphylococcus Aureus Infections- Unmet Needs
20. Methicillin-Resistant Staphylococcus Aureus Infections- Market Drivers and Barriers
21. Methicillin-Resistant Staphylococcus Aureus Infections- Future Perspectives and Conclusion
22. Methicillin-Resistant Staphylococcus Aureus Infections Analyst Views
23. Methicillin-Resistant Staphylococcus Aureus Infections Key Companies
24. Appendix

For further information on the Methicillin Resistant Staphylococcus Aureus Pipeline therapeutics, reach out to Methicillin Resistant Staphylococcus Aureus Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/methicillin-resistant-staphylococcus-aureus-mrsa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Important Links-
Uveitis Market- https://www.delveinsight.com/report-store/uveitis-market
Hidradenitis Suppurativa Market- https://www.delveinsight.com/report-store/hidradenitis-suppurativa-market
Peripheral T-cell Lymphoma Market- https://www.delveinsight.com/report-store/peripheral-t-cell-lymphoma-ptcl-market
Glaucoma Market- https://www.delveinsight.com/report-store/glaucoma-market
Retinitis Pigmentosa Market- https://www.delveinsight.com/report-store/retinitis-pigmentosa-market
Oropharyngeal Cancer Market- https://www.delveinsight.com/report-store/oropharyngeal-cancer-market
Thyroid Cancer Market- https://www.delveinsight.com/report-store/thyroid-cancer-market
Paranasal Sinus Cancer Market- https://www.delveinsight.com/report-store/paranasal-sinus-cancer-market
Castration-resistant Prostate Cancer Market- https://www.delveinsight.com/report-store/castration-resistant-prostate-cancer-crpc-market
Opioid Withdrawal Syndrome Market- https://www.delveinsight.com/report-store/opioid-withdrawal-syndrome-market
Complicated Urinary Tract Infections Market- https://www.delveinsight.com/report-store/complicated-urinary-tract-infections-market
Cervical Dystonia Market- https://www.delveinsight.com/report-store/cervical-dystonia-market
Schizophrenia Market- https://www.delveinsight.com/report-store/schizophrenia-market-insight
Focal Segmental Glomerulosclerosis Market- https://www.delveinsight.com/report-store/focal-segmental-glomerulosclerosis-fsgs-market
Obstructive Sleep Apnea Market- https://www.delveinsight.com/report-store/obstructive-sleep-apnea-osa-market
Severe Hypertriglyceridemia Market- https://www.delveinsight.com/report-store/severe-hypertriglyceridemia-shtg-market
Short Bowel Syndrome Market- https://www.delveinsight.com/report-store/short-bowel-syndrome-market
Complement 3 Glomerulopathy Market- https://www.delveinsight.com/report-store/complement-3-glomerulopathy-c3g-market
Aplastic Anemia Market- https://www.delveinsight.com/report-store/aplastic-anemia-market
Nephrotic Syndrome Market- https://www.delveinsight.com/report-store/nephrotic-syndrome-market
Pulmonary Arterial Hypertension Market- https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-market
Hemophilia A Market- https://www.delveinsight.com/report-store/hemophilia-a2030-market
Complicated Urinary Tract Infections Market- https://www.delveinsight.com/report-store/complicated-urinary-tract-infections-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:- https://www.delveinsight.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Methicillin Resistant Staphylococcus Aureus Pipeline 2024 | Trellis Bioscience, LegoChem Biosciences, Aptorum Group, ContraFect, Crystalgenomics, Cellics Therapeutics, MicuRx, Oxford Antibiotic Group, Destiny Pharma, TSRL, Inc., TAXIS Pharmaceuticals, Bas here

News-ID: 3543729 • Views:

More Releases from DelveInsight Business Research LLP

Cutaneous Lupus Erythematosus Clinical Trials, Emerging Therapies, Key Companies | A Drug Pipeline Analysis Report 2024 | Companies- Sanofi, Bristol Myers Squibb, Merck
Cutaneous Lupus Erythematosus Clinical Trials, Emerging Therapies, Key Companies …
DelveInsight's 'Cutaneous Lupus Erythematosus Pipeline Insight 2024' report provides comprehensive global coverage of available, marketed, and pipeline Cutaneous Lupus Erythematosus therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Cutaneous Lupus Erythematosus pipeline domain. Key Takeaways from the Cutaneous Lupus Erythematosus Pipeline Report Various Cutaneous Lupus Erythematosus pipeline therapies are in various stages of development, and their anticipated
Dravet Syndrome Clinical Trials | A Drug Pipeline Analysis Report 2024 | Companies- Takeda, Eisai, Stoke Therapeutics
Dravet Syndrome Clinical Trials | A Drug Pipeline Analysis Report 2024 | Compani …
DelveInsight's 'Dravet Syndrome Pipeline Insight 2024' report provides comprehensive global coverage of available, marketed, and pipeline Dravet Syndrome therapies in various stages of clinical development; major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Dravet Syndrome pipeline domain. Key Takeaways from the Dravet Syndrome Pipeline Report Over 15+ Dravet Syndrome pipeline therapies are in various stages of development, and their anticipated acceptance in the Dravet
Diabetic Retinopathy Clinical Trials | A Drug Pipeline Analysis Report 2024 | Companies- Kodiak Sciences, Novartis, Regenxbio
Diabetic Retinopathy Clinical Trials | A Drug Pipeline Analysis Report 2024 | Co …
DelveInsight's 'Diabetic Retinopathy Pipeline Insight 2024' report provides comprehensive global coverage of available, marketed, and pipeline Diabetic Retinopathy therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Diabetic Retinopathy pipeline domain. Key Takeaways from the Diabetic Retinopathy Pipeline Report Over 60+ Diabetic Retinopathy pipeline therapies are in various stages of development, and their anticipated acceptance in the Diabetic
Cutaneous T-Cell Lymphoma Clinical Trials | A Drug Pipeline Analysis Report 2024 | Companies- Soligenix, Moleculin Biotech, Innate Pharma, Bioniz, Codiak BioSciences
Cutaneous T-Cell Lymphoma Clinical Trials | A Drug Pipeline Analysis Report 2024 …
DelveInsight's 'Cutaneous T-Cell Lymphoma Pipeline Insight 2024' report provides comprehensive global coverage of available, marketed, and pipeline Cutaneous T-Cell Lymphoma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Cutaneous T-Cell Lymphoma pipeline domain. Key Takeaways from the Cutaneous T-Cell Lymphoma Pipeline Report Over 25+ Cutaneous T-Cell Lymphoma pipeline therapies are in various stages of development, and their

All 5 Releases


More Releases for Staphylococcus

Methicillin-Resistant Staphylococcus Aureus Testing Market Size, Share, Developm …
LP INFORMATION offers a latest published report on Methicillin-Resistant Staphylococcus Aureus Testing Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. According to this study, over the next five years the Methicillin-Resistant Staphylococcus Aureus Testing market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million
Staphylococcus Aureus Testing Market In-Depth Market Research Report 2027
A wide range of human clinical infection caused by Staphylococcus Aureus such as Skin, soft tissue, bacteremia, infective endocarditis and others are the major infection caused by Staphylococcus Aureus. The increased use of Staphylococcus Aureus testing in the diagnosis of staph infection grow rapidly, due to the availability of the various advanced test to screen the pathogen efficiently. There is a number of tests present in the market for Staphylococcus
Methicillin-resistant Staphylococcus Aureus Therapeutics Pipeline Analysis 2018
MRSA infection caused by specific "staph" bacteria that is often resistant to most of antibiotic treatments. S. aureus (SA) is listed as a ‘superbug’ by U.S. Centers for Disease Control and Prevention (CDC). MRSA can either be present harmlessly on the skin (colonization) or enter the body (e.g. through broken skin) and cause an infection. The study analyzed that MRSA infection therapeutics pipeline comprises approximately 52 drug candidates in different
Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market – Driver
Methicillin-Resistant Staphylococcus Aureus (MRSA) is a type of staphylococcus aureus, which became resistant to methicillin, amoxicillin, penicillin, oxacillin, and other such commonly used antibiotics. Staphylococcus aureus harbors on the skin and nasal passage of about one third of the world population, which comprises around 33%, as per Centers for Disease Control and Prevention (CDC) review 2015. MRSA can be classified into two types, based on mode of infection – Hospital
Vancomycin-Resistant Staphylococcus aureus Infections Pipeline Review H1 2017
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline Review, H1 2017, provides an overview of the Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) pipeline landscape. Vancomycin resistant staphylococcus infection is a condition caused by bacteria (germs) . This infection occurs when bacteria, called Staphylococcus aureus or Staph, becomes resistant (not killed) to the antibiotic medicine vancomycin. Risk factors include taking strong antibiotics the wrong
Market Forecast Report on Staphylococcus Aureus Testing Market 2017 – 2027
A wide range of human clinical infection caused by Staphylococcus Aureus such as Skin, soft tissue, bacteremia, infective endocarditis and others are the major infection caused by Staphylococcus Aureus. The increased use of Staphylococcus Aureus testing in the diagnosis of staph infection grow rapidly, due to the availability of the various advanced test to screen the pathogen efficiently. There is a number of tests present in the market for Staphylococcus